Welcome to our dedicated page for Bicara Therapeutics news (Ticker: BCAX), a resource for investors and traders seeking the latest updates and insights on Bicara Therapeutics stock.
Bicara Therapeutics Inc. reports clinical and corporate developments as a clinical-stage biopharmaceutical company developing bifunctional therapies for solid tumors. Its lead program, ficerafusp alfa, is a bifunctional antibody combining an EGFR-directed monoclonal antibody with a domain that binds human TGF-beta, with company updates focused on first-line recurrent or metastatic HPV-negative HNSCC and the FORTIFI-HN01 pivotal trial.
Recurring news also includes quarterly financial results, business updates, public equity financing, common stock and pre-funded warrant offerings, Nasdaq inducement grants, and executive appointments tied to clinical development, medical affairs and commercial readiness.
Bicara Therapeutics (BCAX) granted inducement stock options on September 1, 2026 to two new employees under its 2026 Inducement Plan, in accordance with Nasdaq Listing Rule 5635(c)(4).
The employees received non-qualified options to purchase an aggregate of 380,575 common shares, including 275,000 options granted to newly appointed Chief Legal Officer Gregory Shiferman. The options have an exercise price of $23.42 per share, equal to the September 1, 2026 Nasdaq closing price. One-fourth of each award vests on the first anniversary of the employee’s start date, with the remainder vesting in 12 equal quarterly installments, subject to continued service. These options were issued outside stockholder-approved equity plans under the board-adopted 2026 Inducement Plan and approved by the compensation committee of independent directors.
Bicara Therapeutics (Nasdaq: BCAX) granted an inducement equity award to new Chief Financial Officer Jennifer Larson, effective August 12, 2026, under its 2026 Inducement Plan. The award consists of a non-qualified stock option to purchase 285,000 shares of common stock at an exercise price of $24.63 per share, equal to the Nasdaq closing price on the grant date.
According to Bicara, one-fourth of the option vests on the first anniversary of Larson’s start date, with the balance vesting in 12 equal quarterly installments thereafter, contingent on continued service. The grant was made outside stockholder-approved equity plans under the 2026 Inducement Plan, adopted in January 2026, and was unanimously approved by independent directors in line with Nasdaq Listing Rule 5635(c)(4).
Bicara Therapeutics (Nasdaq: BCAX) reported second quarter 2026 results and announced a broad leadership succession plan aligned with potential commercialization of its lead asset, ficerafusp alfa. President & COO Ryan Cohlhepp will become CEO on January 1, 2027, with current CEO Claire Mazumdar moving to Vice Chair and Strategic Advisor. Tanya Green will become COO, Jenn Larson CFO (effective August 12, 2026), Jenna Cohen Chief Business Officer, and Greg Shiferman Chief Legal Officer (effective August 31, 2026).
According to Bicara, the pivotal FORTIFI-HN01 Phase 3 trial in 1L R/M HPV-negative HNSCC is on track for substantial enrollment by year-end, enabling an interim topline readout in mid-2027. The company initiated the FORTIFI-FLEX alternate dosing study and reported three-year Phase 1/1b data showing an estimated 31% OS at the 1500mg QW dose cohort. Bicara ended June 30, 2026 with $497.3 million in cash, cash equivalents and marketable securities, expects funding into 1H 2029, and recorded Q2 2026 R&D expenses of $45.8 million, G&A of $14.2 million, and a net loss of $55.4 million.
Bicara Therapeutics (Nasdaq: BCAX) announced it will report its second quarter 2026 financial results and provide business updates before the market opens on Tuesday, August 11, 2026. The company will host a conference call at 8:30 a.m. ET the same day to discuss these updates.
Investors can register online to receive dial-in details and a unique PIN for the call. A live webcast will be available via the “Events & Presentations” section of the Investors page on the Bicara website, with a replay accessible for 30 days following the event.
Bicara Therapeutics (Nasdaq: BCAX) appointed Jeremy Bender, Ph.D., MBA, and Christy Oliger to its Board of Directors. Bender most recently served as Chief Executive Officer of Day One Biopharmaceuticals through its 2026 acquisition by Servier, bringing over 20 years of biotechnology strategy and operating experience. Oliger adds more than 30 years of commercial and operating experience from global biopharmaceutical roles, most recently as Senior Vice President of the Oncology Business Unit at Genentech.
According to Bicara Therapeutics, the new directors’ commercial, strategic, and operational expertise is expected to support the company’s transition toward delivering its lead candidate ficerafusp alfa to patients. The company also reported that founding Board member Kiran Mazumdar-Shaw has retired from the Board after contributing early seed capital, strategic guidance, and support that helped advance ficerafusp alfa into a registration-enabling clinical study.
Bicara Therapeutics (Nasdaq: BCAX) granted inducement equity awards to four new employees under its 2026 Inducement Plan, consistent with Nasdaq Listing Rule 5635(c)(4).
The grants cover 191,425 stock options at an exercise price of $28.91 per share, with time-based vesting tied to continued service.
Bicara Therapeutics (Nasdaq:BCAX) reported three-year follow-up from a Phase 1/1b study of ficerafusp alfa plus pembrolizumab in first-line recurrent/metastatic HPV-negative head and neck squamous cell carcinoma.
At 1500mg weekly, estimated three-year overall survival was 31%, with high complete and deep response rates and a generally well-tolerated safety profile, supporting the ongoing FORTIFI-HN01 pivotal program.
Bicara Therapeutics (Nasdaq: BCAX) granted an inducement stock option to new Chief Commercial Officer Christopher Sarchi under its 2026 Inducement Plan, effective May 8, 2026.
The option covers 282,240 shares at an exercise price of $22.58, vesting over four-plus years under Nasdaq Listing Rule 5635(c)(4).
Bicara Therapeutics (Nasdaq: BCAX) reported Q1 2026 results and a business update focused on ficerafusp alfa in HPV-negative head and neck cancer.
FORTIFI-HN01 enrollment is on track for an interim analysis in mid-2027. A new randomized loading/maintenance study is expected to start in Q3 2026. Long-term Phase 1b data will be presented at ASCO 2026, and additional mCRC data are planned for 2H 2026.
Cash, cash equivalents and marketable securities were $539.8 million, boosted by $161.8 million in net public offering proceeds, funding operations into 1H 2029. Q1 R&D was $47.5 million, G&A $12.7 million, and net loss $56.2 million, all higher year over year. Leadership changes include promoting Bill Schelman to Chief Medical Officer and appointing Chris Sarchi as Chief Commercial Officer.
Bicara Therapeutics (Nasdaq: BCAX) will report first quarter 2026 financial results and business updates before the market opens on May 11, 2026. A conference call will follow at 8:30 a.m. ET, with a live webcast and a replay available for 30 days.
Registration is required for dial-in details and a unique PIN; the webcast is available in the Investors & Events section on the company website.